FULLERTON, Calif., May  21, 2026  (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (&#34;Liminatus&#34; or the &#34;Company&#34;) today announced that it has entered into a definitive Merger Agreement dated May 17, 2026, with InnocsAI LLC

LIMN

Liminatus Pharma Announces Proposed Merger with InnocsAI to Expand Oncology Cell Therapy Pipeline

Liminatus Pharma Expands Oncology Pipeline Through InnocsAI Merger

<section class="insight" data-version="1">
 <section data-block="information">
 <h3>Information</h3>
 FULLERTON, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (&amp;#34;Liminatus&amp;#34; or the &amp;#34;Company&amp;#34;) today announced that it has entered into a definitive Merger Agreement dated May 17, 2026, with InnocsAI LLC
 </section>

 <section data-block="ai-summary-paragraph">
 <h3>AI Summary</h3>
 Liminatus Pharma&#039;s merger with InnocsAI aims to enhance its oncology portfolio, introducing advanced CAR-T therapies targeting critical cancer challenges. The transaction, valued at $320 million, promises significant growth opportunities in hematologic cancers and solid tumors, pending necessary approvals.
 </section>

 <section data-block="ai-summary-bullets">
 <h3>Key Points</h3>
 <ul><li>Liminatus Pharma announces merger with InnocsAI to enhance oncology portfolio.</li><li>InnocsAI specializes in CAR-T and antibody-based therapies for cancer treatment.</li><li>Investment valued at approximately $320 million, comprising 1.6 billion shares at $0.20 each.</li><li>Acquisition includes advanced CAR-T therapies targeting hematologic cancers and solid tumors.</li><li>Transaction approval pending shareholder and regulatory clearances.</li></ul>
 </section>

 <section data-block="companies-mentioned">
 <h3>Companies Mentioned</h3>
 <ul><li>InnocsAI LLC (N/A): InnocsAI specializes in CAR-T therapies, enhancing LIMN&#039;s oncology potential.</li></ul>
 </section>

 <section data-block="category">
 <h3>Corporate Developments</h3>
 The transaction falls under &#039;Corporate Developments&#039; as it represents a significant merger aimed at expanding Liminatus&#039;s oncology capabilities, which is vital for future growth in an evolving biotech landscape.
 </section>

 <section data-block="market-moving">
 <h3>Market-Moving</h3>
 <ul><li>Shareholder approval for the merger could significantly drive LIMN&#039;s stock price upward.</li><li>Successful integration and development of InnocsAI&#039;s assets may enhance future revenue potential.</li><li>Regulatory approvals for pipeline therapies could lead to rapid stock appreciation.</li><li>Market sentiment surrounding oncology advancements may influence LIMN&#039;s trading activity.</li></ul>
 </section>

 <section data-block="key-facts">
 <h3>Key Facts</h3>
 <ul><li>Merger agreement signed on May 17, 2026, valued at $320 million.</li><li>InnocsAI to merge into a Delaware subsidiary of Liminatus Pharma.</li><li>Combined assets focus on CAR-T technologies for hematologic and solid tumors.</li><li>IBC101 has received approval for a Phase 1/2a clinical study in Korea.</li><li>Transaction subject to customary closing conditions, including shareholder and regulatory approvals.</li></ul>
 </section>

 <section data-block="trading-thesis">
 <h3>Trading Thesis</h3>
 Invest in LIMN for potential price appreciation driven by enhanced oncology capabilities in the next 12-18 months.
 </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link>FULLERTON, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. ("Liminatus" or the "Company") today announced that it has entered into a definitive Merger Agreement dated May 17, 2026, with InnocsAI LLC ("InnocsAI"), a biotechnology company focused on advanced CAR-T and antibody-based oncology therapies. Under the terms of the Merger Agreement, InnocsAI will merge with and into a newly formed wholly owned Delaware subsidiary of Liminatus, with the subsidiary surviving as a wholly owned subsidiary of the Company. The transaction is intended to expand Liminatus' oncology pipeline with multiple biologic and cellular therapy assets designed to address significant challenges in hematologic cancers and solid tumors. Pursuant to the agreement, the existing members of InnocsAI will receive aggregate consideration consisting of 1.6 billion shares of Liminatus common stock at an issue price of $0.20 per share, representing an aggregate implied transaction value of approximately $320 million, together with contingent value rights representing the right to receive 20% of future net proceeds from certain strategic transactions involving the acquired assets. "This proposed transaction represents a transformational opportunity for Liminatus to expand into next-generation oncology cell therapies," said Chris Kim, Chief Executive Officer of Liminatus Pharma. "InnocsAI's portfolio includes differentiated CAR-T technologies designed to address major limitations in current cancer therapies, including antigen escape, tumor heterogeneity, and the immunosuppressive tumor microenvironment. We believe these assets could position the Company for future development opportunities across both hematologic malignancies and solid tumors." Key Pipeline Assets Included in the Proposed Transaction The assets to be acquired in the Merger include a portfolio of oncology-focused biologic and cellular therapy programs. The portfolio is centered on CAR-T and antibody-related technologies designed to address certain limitations observed in current approaches to hematologic malignancies and solid tumors, including antigen escape, tumor heterogeneity, limited T-cell persistence, tumor microenvironment-mediated suppression, and lineage-restricted target coverage. The Company believes that these assets may provide development opportunities across hematologic oncology, solid tumor indications, and future multi-target platform applications. IBC101. IBC101 is an autologous CD19xCD22 bivalent CAR-T cell therapy candidate designed for relapsed or refractory B-cell malignancies. The product is intended to function as an OR-gate CAR-T therapy, enabling recognition of malignant B cells expressing either CD19 or CD22. According to company materials, IBC101 has received authorization from the Ministry of Food and Drug Safety of the Republic of Korea for a Phase 1/2a clinical study in relapsed or refractory diffuse large B-cell lymphoma, with Seoul St. Mary's Hospital identified as the lead clinical site. IBC101 is designed to address antigen escape and tumor heterogeneity, which are recognized mechanisms of relapse following single-antigen CD19-directed CAR-T therapy. By combining CD19 and CD22 targeting, IBC101 is intended to broaden antigen coverage in B-cell malignancies. Company materials also describe an ex vivo expansion process using IL-7 and IL-15, with the goal of supporting T-cell fitness and persistence. If successfully developed, IBC101 could represent a next-generation hematologic CAR-T candidate with potential applicability in relapsed or refractory DLBCL and other B-cell malignancies. INC101. INC101 is a preclinical autologous bicistronic CAR-T cell therapy candidate for solid tumors based on a dual-antigen MSLNxCD276 design. The construct is designed as an AND-gate system in which mesothelin provides the primary tumor-associated activation signal and CD276, also known as B7-H3, provides a secondary costimulatory signal. This design is intended to improve tumor selectivity by requiring convergence of two tumor-associated signals. The INC101 program is designed to address challenges that have limited CAR-T development in solid tumors, including on-target/off-tumor risk, antigen heterogeneity, tonic signaling, T-cell exhaustion, and tumor microenvironment-mediated suppression. Company materials describe a bicistronic architecture that separates activation and costimulation into two modules and incorporates engineering features intended to reduce signal leakage. A related follow-on construct, INC102, incorporates a dominant-negative TGF-β receptor armoring strategy intended to support T-cell function in TGF-β-rich tumor microenvironments. The proposed development focus includes biomarker-selected solid tumors with mesothelin and CD276 expression, including malignant pleural mesothelioma, ovarian cancer, pancreatic cancer, and other selected solid tumors. CS1 Antibody Platform. The CS1 antibody platform consists of proprietary anti-CS1 monoclonal antibodies intended to serve as an enabling module for the Company's hematologic CAR-T platform. Rather than being positioned primarily as a standalone CS1-directed CAR-T program, the CS1 binders are intended to be combined with the CD19xCD22 bivalent CAR-T backbone to support development of a potential CD19xCD22xCS1 trivalent CAR-T candidate. This strategy is intended to extend the platform from B-cell malignancies into plasma-cell malignancies, including multiple myeloma. CD19 and CD22 are intended to provide coverage of B-cell leukemias and lymphomas, while CS1 is intended to add plasma-cell targeting capability. By integrating these targets into one trivalent CAR-T framework, the Company may be able to bridge B-cell malignancy and plasma-cell malignancy targeting strategies and support broader hematologic oncology platform-development opportunities. Transaction Details The proposed merger has been approved by the boards of directors/managers of both companies and remains subject to customary closing conditions, including shareholder approval, regulatory approvals and other conditions set forth in the Merger Agreement. Additional information regarding the transaction will be included in a Current Report on Form 8-K to be filed by the Company with the U.S. Securities and Exchange Commission. About Liminatus Pharma, Inc. Liminatus Pharma, Inc. is a biopharmaceutical company focused on the development of innovative therapies for oncology and other serious diseases. Forward-Looking Statements Certain statements made in this press release are forward-looking statements. When used in this press release, the words "estimates," "projected," "expects," "anticipates," "forecasts," "plans," "intends," "believes," "seeks," "may," "will," "should," "future," "propose" and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the Company's and InnocsAI's control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Important factors, among others, that may affect actual results or outcomes include: performance of the Company's and InnocsAI's business; the risk that the approval of the stockholders of the Company for the proposed transactions is not obtained; failure to realize the anticipated benefits of the proposed transactions, including as a result of a delay in consummating the proposed transactions; risks relating to the combined company's sources of cash and cash resources; risks relating to the combined company's ability to manage future growth; the effects of competition on the combined company's future business; the Company's ability to maintain compliance with the continued listing requirements of the Nasdaq listing rules in order to prevent its common stock from being delisted from Nasdaq; the outcome of any potential litigation, government and regulatory proceedings, any investigations and inquiries involving the parties to the transactions; the impact of pandemics, global conflicts, the global economic status or tariffs on the Company's or the combined company's business; and those factors discussed in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, which was filed with the SEC on March 31, 2026, and other documents of the Company filed, or to be filed, with the SEC. The Company and InnocsAI do not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Additional Information and Where to Find It The proposed transactions will be submitted to stockholders of the Company for their consideration and approval. The Company intends to file a registration statement (the "Registration Statement") with the U.S. Securities and Exchange Commission (the "SEC") which will include a preliminary proxy statement in connection with the Companys solicitation for proxies for the vote by the Company's stockholders in connection with the proposed transactions and other matters as described in the Registration Statement, as well as a prospectus relating to the offer of the securities to be issued in connection with the proposed transactions. After the Registration Statement is filed and declared effective, the Company will mail a definitive proxy statement and other relevant documents to its stockholders as of the record date established for voting on the proposed transactions. The Company's stockholders and other interested persons are advised to read, once available, the preliminary proxy statement/prospectus and any amendments thereto and, once available, the definitive proxy statement/prospectus, in connection with the Company's solicitation of proxies for its special meeting of stockholders to be held to approve, among other things, the proposed transactions, because these documents will contain important information about the Company, InnocsAI and the proposed transactions. Stockholders may also obtain a copy of the preliminary or definitive proxy statement, once available, as well as other documents filed with the SEC regarding the proposed transactions and other documents filed with the SEC by the Company, without charge, at the SEC's website located at <a href="http://www.sec.gov" title="www.sec.gov">www.sec.gov</a> or by directing a request to the Company. Participants in the Solicitation The Company, InnocsAI and their respective directors, executive officers, and other members of management and employees may, under SEC rules, be deemed to be participants in the solicitations of proxies from the Company's stockholders in connection with the proposed transactions. Information regarding the persons who may, under SEC rules, be deemed participants in the solicitation of the Company's stockholders in connection with the proposed transactions will be set forth in the proxy statement/prospectus to be filed with the SEC in connection with the transactions. You can find more information about the Company's directors and executive officers and their ownership of shares of common stock of the Company in the Company's filings with the SEC, including the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, which was filed with the SEC on March 31, 2026. Additional information regarding the participants in the proxy solicitation and a description of their direct and indirect interests will be included in the proxy statement/prospectus when it becomes available. Shareholders, potential investors and other interested persons should read the proxy statement/prospectus carefully when it becomes available before making any voting or investment decisions. You may obtain free copies of these documents from the sources indicated above. No Offer or Solicitation This press release shall not constitute a solicitation of a proxy, consent, or authorization with respect to any securities or in respect of any proposed transaction. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, or an exemption therefrom. Contacts: Liminatus Pharma, Inc. Chris Kim, CEO — <a href="mailto:info@liminatuspharma.com">info@liminatuspharma.com</a>, (213) 273-5453 <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTcyNDQxMCM3NjE0MzM1IzIzMDM5MjU="></img> <img alt="" src="https://ml.globenewswire.com/media/NzNiNjc2ZmEtYTY5Ny00MTEyLWEzZDUtNDU2MGFhNTE1MzQyLTEzMTU0NzUtMjAyNi0wNS0yMS1lbg==/tiny/Liminatus-Pharma-Inc-.png" referrerpolicy="no-referrer-when-downgrade"></img><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/9ad52a99-f6dd-4ecb-8aa0-15713a0e8788"><img src="https://ml.globenewswire.com/media/9ad52a99-f6dd-4ecb-8aa0-15713a0e8788/small/picture1-png.png" border="0" width="150" height="55" alt="Primary Logo"></img></a>

Liminatus Pharma's merger with InnocsAI aims to enhance its oncology portfolio, introducing advanced CAR-T therapies targeting critical cancer challenges. The transaction, valued at $320 million, promises significant growth opportunities in hematologic cancers and solid tumors, pending necessary approvals.

Liminatus Pharma Announces Proposed Merger with InnocsAI to Expand Oncology Cell Therapy Pipeline

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News